Thiazide Prophylaxis of Urolithiasis
Thiazide Prophylaxis of Urolithiasis
复制标题
噻嗪类药物预防尿石症
DOI：
10.1111/j.0954-6820.1984.tb05023.x
复制
发表时间：
1984
影响因子：
--
通讯作者：
S. Larsen
中科院分区：
文献类型：
--
作者：
E. Lærum;S. Larsen
在挪威的一家全科诊所进行的一项双盲随机研究（中位数3年）中纳入了50例复发性结石形成者，以比较25 mg氢氯噻嗪每日两次给药与安慰剂。安慰剂组新发结石的患者数量显著高于噻嗪组（p=0.05，单侧检验）。如果形成新结石，噻嗪类药物（而非安慰剂）可延长排石间期（p≤0.01）。安慰剂组在治疗期间不形成新结石的概率为45%，噻嗪组为75%。噻嗪的作用似乎与尿钙无关，但对高尿酸血症患者的益处较少。安慰剂组还显示预期的新结石数量大幅减少（p≤0.01），强调了适当对照组的重要性。
Fifty recurrent stone formers were included in a double-blind randomized study (median 3 years) performed in a Norwegian general practice to compare twice daily administration of 25 mg hydrochlorothiazide versus placebo. The number of patients with new stones was significantly higher in the placebo group than in the thiazide group (p=0.05, one-tailed test). If a new stone was formed, thiazide, but not placebo, had the effect of prolonging the stone-free interval (p≤0.01). The probability of not forming a new stone during the treatment period was 45% for the placebo group and 75% for the thiazide group. The thiazide effect seemed to be independent of urinary calcium, but was less beneficial in patients with hyperuricosuria. The placebo group also showed a substantial decrease in the expected number of new stones (p≤0.01), emphasizing the importance of an adequate control group.